Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 7/20 | 0.46 |
| ▸ | ARG2 | P78540 | 6/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893767 | 0.88 | ARG1 (0.63) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894874 | 0.87 | ARG1 (0.62) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894990 | 0.86 | ARG1 (0.61) | ARG1ARG2KCNA3 | |
| SCHEMBL10265869 | 0.80 | ARG1 (0.47) | ARG1ARG2OPRM1 | |
| SCHEMBL10265542 | 0.79 | ARG1 (0.51) | ARG1ARG2 | |
| SCHEMBL10265307 | 0.77 | ARG1 (0.49) | ARG1ARG2 | |
| SCHEMBL20683388 | 0.76 | ARG1 (0.47) | ARG1ARG2KCNA3ADRA1AHTR7 | |
| SCHEMBL6643987 | 0.75 | OPRM1 (0.53) | KCNA3ADRA1AHTR7OPRM1 | |
| SCHEMBL20683332 | 0.75 | ARG1 (0.69) | ARG1ARG2 | |
| SCHEMBL10265570 | 0.74 | PRMT3 (0.51) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885KCNA3 3780/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885KCNA3 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.